$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
帕博西林联合来曲唑治疗乳腺癌延长无进展生存期
2025-10-19 11:44:20
Check Details
依维莫司主要适用于哪些病症?
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗存在BRCA突变卵巢癌
2025-10-19 11:44:20
Check Details
多发性骨髓瘤的患者可服用雷利度胺治疗
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗携带BRCA突变的乳腺癌患者
2025-10-19 11:44:20
Check Details
帕博西林+来曲唑治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕利降低三阴性乳腺癌患者的死亡风险
2025-10-19 11:44:20
Check Details
哌柏西利联合来曲唑转移性乳腺癌的一线治疗方案
2025-10-19 11:44:20
Check Details
哌柏西利联合来曲唑治疗乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼获批治疗转移性胰腺癌患者
2025-10-19 11:44:20
Check Details
帕博西林治疗三阴乳腺癌效果如何?
2025-10-19 11:44:20
Check Details
来曲唑联合拉帕替尼治疗早期乳腺癌
2025-10-19 11:44:20
Check Details
1
2
...
1655
1656
1657
1658
1659
1660
1661
...
4158
4159
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
2
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
3
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
4
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
5
Lapatinib: Proper Administration Guide and Key Precautions
6
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
7
Cemiplimab Storage and Handling Guide
8
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
9
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
10
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
11
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
12
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1